Karyopharm Therapeutics: Funding, Investors & Team (Nov 2026)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
Karyopharm Therapeutics has raised $165M across 1 funding round on record, the most recent an undisclosed round of $165M announced in Dec 2022.
That round is above the $5.0M median round size for Health Care companies tracked on FundedIQ over the last two years.
Karyopharm Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2022.
Karyopharm Therapeutics Funding Rounds
Karyopharm Therapeutics Founders and Leadership Team
Contact details for the Karyopharm Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Karyopharm Therapeutics Funding Compared to Other Health Care Startups
Karyopharm Therapeutics' latest round of $165M is above the median round in Health Care. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Karyopharm Therapeutics in Health Care and Newton
Companies Similar to Karyopharm Therapeutics
ReferWell is a digital health company based in the New York area that makes use of the referable moment, or…
Physician-led medical device company focused on developing enhanced electroporation therapy for advanced…
SymKardia is healthcare manufacturing company that develops medical device to treat cardiac arrhythmias.
We are dedicated to revolutionizing gastric bypass. From the procedure to the recovery, our skilled team of…
BEKhealth harnesses its AI-powered chart abstraction and patient-matching platform to help organizations…
Treso operates as a financial software provider that develops an integrated financial operating system…
Optain produces medical tools and technology with the aim of providing healthcare access to everyone,…
Using technology and the best professionals, Wally, a membership-based dental care service, offers proactive,…
PreciseDx is a unique Cancer Risk Stratification company that offers personalized risk information by…
General Medicine provides a convenient and straightforward way to access top-quality healthcare services with…
Forty million men in the US and over 500 million worldwide suffer from urinary obstruction related to benign…
SedMed provides medical devices that support safer toileting transfers and help prevent falls for individuals…
Karyopharm Therapeutics Funding FAQs
What does Karyopharm Therapeutics do?
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIO® (selinexor), received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for selinexor for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
How much funding has Karyopharm Therapeutics raised?
Karyopharm Therapeutics has raised $165M across 1 round on record. The most recent is an undisclosed round of $165M announced in Dec 2022.
When did Karyopharm Therapeutics last raise funding?
Karyopharm Therapeutics' most recent funding round on record is an undisclosed round of $165M, announced in Dec 2022.
Who founded Karyopharm Therapeutics?
FundedIQ lists Sharon Shacham (Founder) at Karyopharm Therapeutics.
Where is Karyopharm Therapeutics headquartered?
Karyopharm Therapeutics is based in Newton, Massachusetts, United States.
How many employees does Karyopharm Therapeutics have?
Karyopharm Therapeutics is in the 251-500 employee band.
How does Karyopharm Therapeutics' funding compare to other Health Care startups?
Karyopharm Therapeutics' latest round of $165M is above the $5.0M median round size for Health Care companies on FundedIQ across 3,662 tracked companies over the last two years.
About FundedIQ's Karyopharm Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Karyopharm Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.